Anti-Mouse IFNAR-1 - Purified in vivo PLATINUM™ Functional Grade
| Code | Size | Price |
|---|
| LEI-I-1188-1.0mg | 1.0 mg | £283.00 |
Quantity:
| LEI-I-1188-5.0mg | 5.0 mg | £456.00 |
Quantity:
| LEI-I-1188-25mg | 25 mg | £1,335.00 |
Quantity:
| LEI-I-1188-50mg | 50 mg | £1,938.00 |
Quantity:
| LEI-I-1188-100mg | 100 mg | £2,741.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: MAR1-5A3
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Blocking
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Immunoprecipitation (IP)
- In Vivo Assay
- Western Blot (WB)
Shipping:
2-8°C
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Further Information
Antigen Distribution:
IFNAR1 and IFNAR2 are coexpressed on nearly all cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified in vivo Functional Grade, in vivo PLATINUM™
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Plasmid DNA encoding murine IFNAR1 extracellular domain
Long Description:
IFNAR1 is a type I membrane protein, that in conjunction with IFNAR2, makes up the heterodimeric receptor that binds all type I IFNs, which includes IFN α and β. Binding and activation of the receptor stimulates Janus protein kinases, which leads to the phosphorylation of several other proteins, namely STAT1 and STAT2. IFNAR1 has also been shown to interact with PRMT1 and Tyrosine kinase 2. Type I IFNs are a family of cytokines that have been shown to promote anti-viral, anti-microbial, anti-tumor and autoimmune responses In vivo.
NCBI Gene:
15975
Purity:
?98% monomer by analytical SEC, >95% by SDS Page
Target:
IFNAR1
References
1.) Beaver, Jacob T. et al. (2020) Human Vaccines & Immunotherapeutics 16:9, 2092-2108 Article Link
2.) Theofilopoulos, AN. et al. (2012) J Immunol. 189: 000?000. Article Link
3.) Oldstone, Michael B. A. et al. (2017) Proc Natl Acad Sci U S A. 114(14): 3708?3713. PubMed
4.) Schreiber, RD et al. (2015) PLoS One.10(5):e0128636PubMed
5.) Shin, Haina et al. (2018) J Virol. 92(7): e00038-18. PubMed
6.) Crack, Peter J. et al. (2016) eNeuro 10.1523/ENEURO.0128-15.2016 Article Link
7.) Sheehan, K. C. F. et al. (2006) JICR 26(11):804
8.) Dunn, G. P. et al. (2005) Nat. Immunol. 6(7):722
9.) Fenner, J. E. et al. (2006) Nat. Immunol. 7(1):33
10.) Biron, C. A. et al. (2007) J Exp Med. 204(10): 2383
11.) Sharma S. et al. (2020) Human Vaccines & Immunotherapeutics 16(9):2196-2203 Journal Link
12.) Cliffe, A. et al. (2021) EMBO Reports 22(9):e52547 Journal Link